SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Map with different syringes. Covid 19 and pandemic vaccination concept. Vector illustration
Vaccines
UK Patent Win Over GSK Boosts Pfizer in Global RSV Vaccine Fight
A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, positioning both companies to compete for that market and laying down a marker for ongoing legal clashes in other parts of the world.
November 20, 2024
 · 
4 min read
 · 
Nick Paul Taylor
Self-knowledge, exploration of own soul, psyche, illumination of hidden in shadow.
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Lungs health and pulmonology as a respiratory medicine conept for pulmonary science and lung cancer or respiration disease and bronchi breathing or asthma symbol in a 3D illustration style.
Business
Regeneron and Sanofi’s Dupixent Tipped to Dominate COPD Biologics Market
Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into significant sales, with GlobalData predicting Dupixent’s COPD revenues will top $6.5 billion within 10 years.
October 15, 2024
 · 
3 min read
 · 
Nick Paul Taylor
Pictured: MRI images of the brain for neurological
Drug Development
Novartis’ Lutathera Radiopharma Therapy Improves Survival in Difficult-to-Treat Brain Tumors
Six months after treatment with the radiopharmaceutical therapy, 77.8% of patients with meningioma were alive and had not experienced further disease progression, beating the 26% benchmark established in earlier studies.
September 30, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Johnson & Johnson's business center in Switzerland
Drug Development
J&J Posts Positive Phase III Results for Carvykti and Darzalex Faspro in Multiple Myeloma Trials
Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual disease-negativity, boosting the prospects of two key growth drivers for the company.
September 30, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Hands in black and white dropping a collection of pills on a pink background
Weight loss
Obesity Pill Race Heats Up as Novo, Roche and Terns Share Data
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, but the comparisons are rife with confounding variables, leaving analysts unsure about where to place their bets.
September 17, 2024
 · 
4 min read
 · 
Nick Paul Taylor
illustration of hands reaching for a semaglutide injector over an image of the Earth
Policy
What Expanded CVD Medicare Coverage May Mean for Novo Nordisk’s Wegovy
A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, but analysts remain dubious of the estimate.
September 11, 2024
 · 
6 min read
 · 
Nick Paul Taylor
Futuristic Cyber Abstracy Eye Background 4K
Business
Roche and Regeneron Square Off in Lucrative Eye Disease Market
Analysts expect the companies’ Vabysmo and Eylea HD to generate a combined $13.2 billion by 2030 in the vascular endothelial growth A therapy market, as healthcare providers and patients switch from older products.
September 4, 2024
 · 
6 min read
 · 
Nick Paul Taylor
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Moderna Lays Foundations for Growth, but Can It Turn Strategy Into Execution?
The vaccine maker is competing with well-established rivals in markets that have a mix of demand issues as well as commercial and structural headwinds, as the biotech looks to establish new growth drivers.
August 28, 2024
 · 
6 min read
 · 
Nick Paul Taylor
Lonely drunk woman sitting on bar counter feels depressed spends time with strong alcoholic beverages holds glass drinking booze having dependence, addiction. Concept of alcoholism and social problems
psychedelics
Atai Touts Early Data on Psychedelic Depression Drug, Plans Phase II Trial
On the heels of last week’s FDA rejection of Lykos’ MDMA-assisted PTSD therapy, Atai announced Tuesday positive preliminary results for its DMT-based treatment for depression from a Phase Ib study.
August 13, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Entrance to Pfizer's office in Belgium
RSV
Pfizer Nabs Pivotal Phase III Win for RSV Vaccine in Immunocompromised Adults
Pfizer on Monday reported a “strong neutralizing response” against both subtypes of respiratory syncytial virus across all cohorts and age groups, according to topline data.
August 12, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Handshake over a deal/iStock, PeopleImag
Mergers & acquisitions
Recursion, Exscientia Merge to Create AI-Enabled Biotech
Armed with a combined $850 million in cash, the companies said Thursday the resulting biotech will have a pipeline that could deliver 10 clinical readouts over the next 18 months.
August 8, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Money growth/iStock, RomoloTavani
Funding
Symbiotic Capital Launches With More Than $600M to Provide Life Science Loans
Biotech entrepreneur Arie Belldegrun and former Roche CEO Franz Humer are part of the credit firm’s push to provide companies with another source of funding, Symbiotic Capital announced Tuesday.
August 6, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Bayer's global pharmaceuticals headquarters in Germany
Drug Development
Bayer’s Finerenone Hits Primary Endpoint in Phase III Heart Failure Trial
With the late-stage win, Bayer announced Monday that it plans to talk to regulators about seeking approval in an indication that is central to its $3 billion-plus peak sales forecast.
August 5, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Handshake in front of raining money / Ta
Deals
Otsuka Pays Up to $1.1B to Buy Jnana, Adds Drug Discovery Capabilities
With an upfront $800 million payment and $325 million in potential milestones, Otsuka Pharmaceutical is acquiring Jnana Therapeutics’ drug discovery platform and rare disease candidate, the companies announced Thursday.
August 1, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Load More